Arsanis to Present at the Cowen and Company 37th Annual Health Care Conference

08:00 EST 1 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
Arsanis, Inc., a clinical-stage biopharmaceutical company developing targeted monoclonal antibodies (mAbs) for pre-emptive and post-infection treatment of serious infectious diseases, announced today that René Russo, PharmD, BC...

Other Sources for this Article

Media Contact:
Ten Bridge Communications
Krystle Gibbs, 508-479-6358
Investor Contact:
Michael Gray, 781-819-5201
Chief Financial and Chief Business Officer


More From BioPortfolio on "Arsanis to Present at the Cowen and Company 37th Annual Health Care Conference"

Quick Search


Relevant Topics

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Monoclonal antibodies MAbs
Monoclonal antibodies recognise and attach to specific proteins produced by cells.  Types of monoclonal antibodies used to treat cancer cells: Block cell dividing dividing signals Transport cancer drugs or radiation to cancer cells Tr...